Grace Therapeutics (GRCE) vs MindWalk (HYFT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Grace Therapeutics (GRCE) has outperformed MindWalk (HYFT) over the past year, losing 46.4% versus a loss of 59.0%. Over five years, GRCE leads with a -79.3% price change compared with -89.3% for HYFT. Grace Therapeutics is the larger company by market cap ($36.0 million vs $32.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GRCE | HYFT |
|---|---|---|
| Share price | $1.71 | $0.6844 |
| Market cap | $35.97M | $32.56M |
| 1-day change | -0.58% | -14.27% |
| YTD return | -50.58% | -62.40% |
| 1-year return | -46.39% | -59.02% |
| 5-year return | -79.35% | -89.34% |
| EPS (TTM) | $-1.16 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-7.79M | — |
| 52-week high | $5.18 | $2.99 |
| 52-week low | $1.64 | $0.64 |
| Distance from 52-week high | -66.99% | -77.11% |
| Analyst consensus | none | none |
| Avg. price target upside | +243.27% | +532.67% |
| Average volume | 119.27K | 257.86K |
| Shares outstanding | 21.04M | 47.57M |
| Employees | 5 | 74 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GRCE has outperformed HYFT by 12.6 percentage points over the past year.
About Grace Therapeutics
GRCE stock →Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About MindWalk
HYFT stock →MindWalk Holdings Corp. operates as a bio-native AI company.
Health Care · Biotechnology: Pharmaceutical Preparations · 74 employees
GRCE vs HYFT FAQ
Which is bigger, Grace Therapeutics or MindWalk?
Grace Therapeutics (GRCE) is larger, with a market capitalization of $35.97M compared with $32.56M for MindWalk (HYFT).
Which stock has performed better over the past year, GRCE or HYFT?
GRCE returned -46.39% over the past 12 months, compared with -59.02% for HYFT (price return, excluding dividends). Past performance does not predict future results.
Are Grace Therapeutics and MindWalk in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.